Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) has been given an average recommendation of “Moderate Buy” by the fourteen research firms that are currently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $117.8182.

Several research firms have issued reports on DNTH. Wolfe Research reaffirmed an “outperform” rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. Wedbush upped their price objective on shares of Dianthus Therapeutics from $103.00 to $105.00 and gave the company an “outperform” rating in a research note on Wednesday, May 6th. HC Wainwright raised their target price on shares of Dianthus Therapeutics from $47.00 to $130.00 and gave the stock a “buy” rating in a research report on Monday, March 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Dianthus Therapeutics in a research note on Monday, April 20th. Finally, Robert W. Baird boosted their price target on Dianthus Therapeutics from $67.00 to $132.00 and gave the company an “outperform” rating in a report on Tuesday, March 10th.

Dianthus Therapeutics Stock Performance

DNTH traded up $3.27 on Tuesday, hitting $96.61. 398,287 shares of the company were exchanged, compared to its average volume of 981,180. Dianthus Therapeutics has a fifty-two week low of $18.08 and a fifty-two week high of $98.70. The firm has a market capitalization of $5.28 billion, a P/E ratio of -23.44 and a beta of 1.20. The business’s fifty day moving average is $86.77 and its 200 day moving average is $70.39.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its quarterly earnings results on Tuesday, May 5th. The company reported ($0.85) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.07) by $0.22. The company had revenue of $0.46 million during the quarter, compared to the consensus estimate of $0.40 million. Dianthus Therapeutics had a negative net margin of 12,998.50% and a negative return on equity of 27.30%. Analysts forecast that Dianthus Therapeutics will post -3.82 EPS for the current fiscal year.

Insider Buying and Selling at Dianthus Therapeutics

In related news, EVP Ryan Savitz sold 8,224 shares of Dianthus Therapeutics stock in a transaction on Thursday, April 9th. The stock was sold at an average price of $89.84, for a total value of $738,844.16. Following the transaction, the executive vice president owned 8,224 shares in the company, valued at approximately $738,844.16. This trade represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Adam M. Veness sold 30,000 shares of the business’s stock in a transaction that occurred on Wednesday, June 17th. The stock was sold at an average price of $80.80, for a total transaction of $2,424,000.00. Following the sale, the senior vice president owned 30,000 shares of the company’s stock, valued at approximately $2,424,000. This represents a 50.00% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 64,754 shares of company stock worth $5,566,993 in the last quarter. 3.02% of the stock is owned by insiders.

Institutional Investors Weigh In On Dianthus Therapeutics

A number of hedge funds have recently bought and sold shares of the business. Fairmount Funds Management LLC raised its position in shares of Dianthus Therapeutics by 22.2% in the 3rd quarter. Fairmount Funds Management LLC now owns 3,307,191 shares of the company’s stock valued at $130,138,000 after purchasing an additional 600,000 shares in the last quarter. Vestal Point Capital LP raised its holdings in Dianthus Therapeutics by 88.2% in the second quarter. Vestal Point Capital LP now owns 3,200,000 shares of the company’s stock valued at $59,616,000 after acquiring an additional 1,499,931 shares in the last quarter. Wellington Management Group LLP boosted its stake in Dianthus Therapeutics by 3,366.9% during the 3rd quarter. Wellington Management Group LLP now owns 2,577,662 shares of the company’s stock valued at $101,431,000 after acquiring an additional 2,503,311 shares during the last quarter. Vanguard Group Inc. boosted its stake in Dianthus Therapeutics by 24.7% during the 4th quarter. Vanguard Group Inc. now owns 2,048,452 shares of the company’s stock valued at $84,417,000 after acquiring an additional 406,254 shares during the last quarter. Finally, TCG Crossover Management LLC grew its holdings in Dianthus Therapeutics by 11.7% during the 3rd quarter. TCG Crossover Management LLC now owns 1,676,624 shares of the company’s stock worth $65,975,000 after acquiring an additional 175,000 shares in the last quarter. Institutional investors and hedge funds own 47.53% of the company’s stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.